Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $698000.0.

  • Utah Medical Products' Other Non Operating Income fell 1650.72% to $698000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$655000.0, marking a year-over-year decrease of 22107.21%. This contributed to the annual value of -$174000.0 for FY2024, which is 16796.88% down from last year.
  • Utah Medical Products' Other Non Operating Income amounted to $698000.0 in Q3 2025, which was down 1650.72% from $640000.0 recorded in Q2 2025.
  • Utah Medical Products' Other Non Operating Income's 5-year high stood at $915000.0 during Q1 2024, with a 5-year trough of -$2.7 million in Q4 2024.
  • Moreover, its 5-year median value for Other Non Operating Income was $198000.0 (2022), whereas its average is $121684.2.
  • Over the last 5 years, Utah Medical Products' Other Non Operating Income had its largest YoY gain of 840000.0% in 2023, and its largest YoY loss of 113937.5% in 2023.
  • Over the past 5 years, Utah Medical Products' Other Non Operating Income (Quarter) stood at -$130000.0 in 2021, then dropped by 23.08% to -$160000.0 in 2022, then plummeted by 1139.38% to -$2.0 million in 2023, then plummeted by 36.06% to -$2.7 million in 2024, then skyrocketed by 125.87% to $698000.0 in 2025.
  • Its Other Non Operating Income was $698000.0 in Q3 2025, compared to $640000.0 in Q2 2025 and $705000.0 in Q1 2025.